GlycoMimetics Revenue vs. Cash Per Share
| GLYC Stock | USD 0.32 0.01 3.03% |
For GlycoMimetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of GlycoMimetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well GlycoMimetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between GlycoMimetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of GlycoMimetics over time as well as its relative position and ranking within its peers.
GlycoMimetics |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
GlycoMimetics Cash Per Share vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining GlycoMimetics's current stock value. Our valuation model uses many indicators to compare GlycoMimetics value to that of its competitors to determine the firm's financial worth. GlycoMimetics is rated below average in revenue category among its peers. It is rated below average in cash per share category among its peers . The ratio of Revenue to Cash Per Share for GlycoMimetics is about 8,696 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the GlycoMimetics' earnings, one of the primary drivers of an investment's value.GlycoMimetics Revenue vs. Competition
GlycoMimetics is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 161.38 Million. GlycoMimetics adds roughly 10,000 in revenue claiming only tiny portion of equities under Health Care industry.
GlycoMimetics Cash Per Share vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
GlycoMimetics |
| = | 10 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
GlycoMimetics |
| = | 1.15 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
GlycoMimetics Cash Per Share Comparison
GlycoMimetics is currently under evaluation in cash per share category among its peers.
GlycoMimetics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in GlycoMimetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, GlycoMimetics will eventually generate negative long term returns. The profitability progress is the general direction of GlycoMimetics' change in net profit over the period of time. It can combine multiple indicators of GlycoMimetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland. Glycomimetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people.
GlycoMimetics Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on GlycoMimetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of GlycoMimetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the GlycoMimetics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in GlycoMimetics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
Use Investing Themes to Complement your GlycoMimetics position
In addition to having GlycoMimetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Junk Bonds Funds Thematic Idea Now
Junk Bonds Funds
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
To fully project GlycoMimetics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of GlycoMimetics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include GlycoMimetics' income statement, its balance sheet, and the statement of cash flows.